Eliem Therapeutics Operating Income 2021-2024 | CLYM
Eliem Therapeutics operating income from 2021 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Eliem Therapeutics Annual Operating Income
(Millions of US $) |
| 2023 |
$-40 |
| 2022 |
$-45 |
| 2021 |
$-36 |
| 2020 |
$-21 |
Eliem Therapeutics Quarterly Operating Income
(Millions of US $) |
| 2024-06-30 |
$-56 |
| 2024-03-31 |
$-3 |
| 2023-12-31 |
$-5 |
| 2023-09-30 |
$-5 |
| 2023-06-30 |
$-7 |
| 2023-03-31 |
$-23 |
| 2022-12-31 |
$-10 |
| 2022-09-30 |
$-9 |
| 2022-06-30 |
$-14 |
| 2022-03-31 |
$-13 |
| 2021-12-31 |
$-11 |
| 2021-09-30 |
$-9 |
| 2021-06-30 |
$-9 |
| 2021-03-31 |
$-7 |
| 2020-12-31 |
|
| 2020-09-30 |
$-2 |
| 2020-06-30 |
$-2 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.342B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
